Monopar Drops Lead Candidate after Disappointing Phase III Analysis

Monopar Therapeutics is dropping its lead candidate, Validive, being studied in a Phase III trial to treat severe oral mucositis (SOM) in oropharyngeal cancer patients undergoing chemoradiotherapy.